BMProbe™ Platform Development

About Invicol

Invicol is an innovative, privately-held biotech company pioneering an in vivo approach to liquid biopsy. Its core technology, the BMProbe™, is a probe inserted into a patient's cubital vein to capture rare circulating cells from a significantly larger blood volume than standard blood draws, promising superior sensitivity for early cancer detection and cardiovascular monitoring. The company is in a pre-revenue, pre-clinical/development stage, advancing its platform through collaborative R&D projects with academic partners like Charité and Freie Universität Berlin, supported by German public grants. Invicol's success hinges on clinical validation, regulatory approval, and demonstrating a clear advantage over established in vitro diagnostic competitors.

About Invicol

Invicol is an innovative, privately-held biotech company pioneering an in vivo approach to liquid biopsy. Its core technology, the BMProbe™, is a probe inserted into a patient's cubital vein to capture rare circulating cells from a significantly larger blood volume than standard blood draws, promising superior sensitivity for early cancer detection and cardiovascular monitoring. The company is in a pre-revenue, pre-clinical/development stage, advancing its platform through collaborative R&D projects with academic partners like Charité and Freie Universität Berlin, supported by German public grants. Invicol's success hinges on clinical validation, regulatory approval, and demonstrating a clear advantage over established in vitro diagnostic competitors.

Therapeutic Areas